None listed
Conditions
Interventions
Intravenous tigecycline will be given
Group name:imipenem / cilastatin Type of group
Intravenous imipenem / cilastatin will be administered.
Sponsors
LABORATORIOS WYETH S.A.,
Eligibility
Inclusion criteria
Inclusion criteria: Men or women interned,> 18 years of age. The subject of having undergone, or should have planned, a laparotomy, a laparoscopy or a percutaneous drainage of an intra-abdominal abscess. Subjects with a complicated intra-abdominal infection The subject received no more than one dose of the parenteral antibiotic
Exclusion criteria
Exclusion criteria: An active or treated leukemia, or a malignant systemic disease that required chemotherapy, immunotherapy, radiotherapy or antineoplastic therapy during the previous year. Early discharge that shortened the intemacion to a lapse of less than 5 days. The presence of any uncontrolled disease of the nervous system central.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Aerobic and anaerobic crops. Measure:The safety and efficacy of tigecycline, with the combination of imipenem / cilastatin, in the treatment of complicated intra-abdominal infections of inpatients. Timepoints:week 5 ± 1 week after the administration of the first dose of the study drug. | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:Aerobic and anaerobic crops. Measure:In vitro sensitivity to tigecycline for a spectrum of pathogenic bacteria that cause complicated intra-abdominal infections. Timepoints:week 5 ± 1 week after the administration of the first dose of the study drug. | — |
Countries
Argentina, Brazil, Canada, Chile, Peru, United States
Outcome results
None listed